Ansquer JC - Search Results

1

Fibrates and microvascular complications in diabetes--insight from the FIELD study.

Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Ansquer JC, et al. Curr Pharm Des. 2009;15(5):537-52. doi: 10.2174/138161209787315701. Curr Pharm Des. 2009. PMID: 19199980 Review.

2

Fibrates and statins in the treatment of diabetic retinopathy.

Ansquer JC, Crimet D, Foucher C. Ansquer JC, et al. Curr Pharm Biotechnol. 2011 Mar 1;12(3):396-405. doi: 10.2174/138920111794480570. Curr Pharm Biotechnol. 2011. PMID: 20939802 Review.

3

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Ansquer JC, et al. Am J Kidney Dis. 2005 Mar;45(3):485-93. doi: 10.1053/j.ajkd.2004.11.004. Am J Kidney Dis. 2005. PMID: 15754270 Clinical Trial.

4

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

Ansquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Ansquer JC, et al. Am J Kidney Dis. 2008 Jun;51(6):904-13. doi: 10.1053/j.ajkd.2008.01.014. Epub 2008 Apr 2. Am J Kidney Dis. 2008. PMID: 18501783 Clinical Trial.

5

Fenofibrate, homocysteine and renal function.

Foucher C, Brugère L, Ansquer JC. Foucher C, et al. Among authors: ansquer jc. Curr Vasc Pharmacol. 2010 Sep;8(5):589-603. doi: 10.2174/157016110792006987. Curr Vasc Pharmacol. 2010. PMID: 20507276 Review.

6

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Ansquer JC, Corda C, Le Malicot K, Jessent V. Ansquer JC, et al. Curr Ther Res Clin Exp. 2009 Apr;70(2):71-93. doi: 10.1016/j.curtheres.2009.03.002. Curr Ther Res Clin Exp. 2009. PMID: 24683220 Free PMC article.

7

Effects of fenofibric acid on diabetic macular edema: the MacuFen study.

Massin P, Peto T, Ansquer JC, Aubonnet P, MacuFEN Study Investigators FT. Massin P, et al. Among authors: ansquer jc. Ophthalmic Epidemiol. 2014 Oct;21(5):307-17. doi: 10.3109/09286586.2014.949783. Epub 2014 Aug 18. Ophthalmic Epidemiol. 2014. PMID: 25133794 Clinical Trial.

8

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; DAIS investigators. Foucher C, et al. Among authors: ansquer jc. Pharmacogenetics. 2004 Dec;14(12):823-9. doi: 10.1097/00008571-200412000-00005. Pharmacogenetics. 2004. PMID: 15608561

9

Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers.

Foucher C, Schiffer E, Mischak H, Ansquer JC, Wilbraham D. Foucher C, et al. Among authors: ansquer jc. Proteomics Clin Appl. 2011 Apr;5(3-4):159-66. doi: 10.1002/prca.201000076. Epub 2011 Feb 24. Proteomics Clin Appl. 2011. PMID: 21360683 Clinical Trial.

10

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.

Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators. Waldman B, et al. Among authors: ansquer jc. Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26. Lancet Diabetes Endocrinol. 2018. PMID: 29496472 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page